News

Kurin, Inc. Receives Allowance from United States Patent and Trademark Office of Additional Claims to its Innovative Blood Culture Collection Device.

Kurin, Inc. Reports Record Revenues

Kurin, Inc. Receives Supplier Horizon Award from Premier Inc.

Kurin, Inc. continues sales growth with record month.

Kurin, Inc. Announces Agreement with Intalere for Kurin Lock to impact contaminated blood cultures

Kurin, Inc. Announces Agreement with Vizient for Kurin Lock to help reduce contaminated blood cultures

Kurin, Inc. receives FDA 510k clearance for its push-button needle

Kurin, Inc. Announces Hire of EVP Operations Amid Record Growth

Kurin, Inc. Reports Record Third Quarter Revenues

Kurin, Inc. receives CE Mark for its novel Kurin Lock®

Kurin Inc. Responds to Allegations Published by Magnolia Medical Regarding Patent Infringement

Kurin, Inc. CEO Addresses Patent Infringement Lawsuit Brought by Magnolia Medical

Kurin, Inc. receives FDA 510k clearance for its novel Kurin Lock with peripheral IV infusion set.

Kurin, Inc. announces clinical results on Kurin® efficacy from Central Texas Veterans Health Care System

Kurin, Inc. Announces Agreement with Premier for Kurin Lock® to help impact contaminated blood cultures

Kurin, Inc. Announces Educational Website on the Importance of Improving Value of the Blood Culture Test

Clinical results of Kurin specimen diversion technology signal a shift in the blood culture collection standard of care.

Kurin CEO responds to Magnolia Medical Countersuit Press Release

Kurin, Inc. Receives Allowance from United States Patent and Trademark Office for Patent on Innovative Blood Culture Collection Device

Kurin, Inc. announces clinical study results of the Kurin Lock™ blood culture initial specimen diversion device at the APIC Annual Conference.

1 2

ML-021 Rev A